← Back to home

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS

Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS explained in plain language.

Never miss a new study

Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS trials appear

Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Breakthrough drug trial aims to reverse liver scarring in cirrhosis patients

Disease control Recruiting now

This study is testing whether a medication called pegozafermin can help reduce liver scarring in people with advanced fatty liver disease that has progressed to cirrhosis. Researchers will enroll 762 adults with compensated cirrhosis from MASH (formerly called NASH) to receive ei…

Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS

Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control

Last updated Apr 06, 2026 10:20 UTC

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS

Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) / NONALCOHOLIC STEATOHEPATITIS (NASH) WITH COMPENSATED CIRRHOSIS trials appear

Breakthrough drug trial aims to reverse liver scarring in cirrhosis patients